Metharbital

Metharbital

SCHEMBL78867

CCC1(CC)C(=O)NC(=O)N(C)C1=O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Metharbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.60
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
ELANE P08246 7/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metharbital SCHEMBL28086124 0.83 LMNA (0.55) ATMLMNATSHRCYP2C19ELANE
Metharbital SCHEMBL4885996 0.83 LMNA (0.59) ATMLMNASMN1; SMN2ELANEMEN1
Mephobarbital SCHEMBL1004749 0.79 LMNA (0.86) ATMLMNATSHRCYP2C19ELANE
SCHEMBL11677956 0.78 SMN1; SMN2 (0.46) ATMLMNASMN1; SMN2TSHRCYP2C19
SCHEMBL31213553 0.76 LMNA (0.48) ATMLMNASMN1; SMN2CYP2C19ELANE
SCHEMBL2049685 0.75 GABRA1 (0.41) ATMLMNASMN1; SMN2MEN1KMT2A
SCHEMBL9334263 0.74 LMNA (0.46) ATMLMNASMN1; SMN2TSHRCYP2C19
SCHEMBL11730000 0.73 ATM (0.50) ATMLMNATSHRELANEALDH1A1
SCHEMBL31509083 0.72 LMNA (0.78) ATMLMNASMN1; SMN2TSHRCYP2C19
SCHEMBL11677957 0.70 LMNA (0.47) ATMLMNASMN1; SMN2ELANEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5204 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3441087-B1 METHODS OF TREATING CHRONIC PAIN TEVA PHARMACEUTICALS INT GMBH (CH) 2025-02-19 EP claimed
US-20230218623-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-07-13 US claimed
EP-4146656-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF Syneurx International (Taiwan) Corp. (TW) 2023-03-15 EP claimed
WO-2022164850-A1 COMPOUNDS TO PREVENT OR TREAT SARS-CoV-2 VARIANT INFECTION UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2022-08-04 WO claimed
EP-3618813-B1 IMPROVED EXTENDED RELEASE HIGHLY LOADED DRUG COMPOSITIONS LUBRIZOL ADVANCED MAT INC (US) 2022-07-06 EP claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
US-20220016035-A1 Extended Release Highly Loaded Drug Compositions LUBRIZOL ADVANCED MATERIALS, INC. (US) 2022-01-20 US claimed
WO-2021224830-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (CN) 2021-11-11 WO claimed
EP-3810184-A2 METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE University of Rochester (US) 2021-04-28 EP claimed
WO-2021060998-A1 PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY, AND THE USE OF J05 ATC GROUP SUBSTANCES IN TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY CHUPTYŚ CONTISSI, Janusz (PL) 2021-04-01 WO claimed
EP-0942752-A1 ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN Algos Pharmaceutical Corporation (US) 1999-09-22 EP claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
WO-1998007447-A1 ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN ALGOS PHARMACEUTICAL CORPORATION (US) 1998-02-26 WO claimed
US-5700410-A Method of manufacturing wax matrices NIPPON SHINYAKU CO., LTD. (JP) 1997-12-23 US claimed
EP-0580860-B1 METHOD OF MANUFACTURING SOLID DISPERSION NIPPON SHINYAKU CO LTD (JP) 1997-10-22 EP claimed
US-4690824-A Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range REDI-ROWELL, INC. (US) 1987-09-01 US claimed
EP-0154631-A4 PROCESS FOR SELECTIVE NITRILE REDUCTION. AMERICAN HOSPITAL SUPPLY CORP (US) 1985-11-25 EP claimed
EP-0154631-A1 PROCESS FOR SELECTIVE NITRILE REDUCTION AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1985-09-18 EP claimed
WO-1985000605-A1 PROCESS FOR SELECTIVE NITRILE REDUCTION AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1985-02-14 WO claimed
US-4126684-A 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE CIBA-GEIGY CORPORATION (US) 1978-11-21 US claimed